Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases

ERBB2 amplification has been identified in ∼5% of KRAS wild-type colorectal cancers (CRCs). A recent clinical trial showed response to HER2-directed therapy in a subset of ERBB2-amplified metastatic CRCs resistant to chemotherapy and EGFR-directed therapy. With the aim of better understanding mechan...

Descripción completa

Detalles Bibliográficos
Autores principales: Owen, Daniel R., Wong, Hui-li, Bonakdar, Melika, Jones, Martin, Hughes, Christopher S., Morin, Gregg B., Jones, Steven J.M., Renouf, Daniel J., Lim, Howard, Laskin, Janessa, Marra, Marco, Yip, Stephen, Schaeffer, David F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2018
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880263/
https://www.ncbi.nlm.nih.gov/pubmed/29438965
http://dx.doi.org/10.1101/mcs.a002535

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880263/
https://www.ncbi.nlm.nih.gov/pubmed/29438965
http://dx.doi.org/10.1101/mcs.a002535

Ejemplares similares